There are several research clinics and institutes that are seeking participants for their studies and clinical trials right now! Please see below to find a clinical trial that appropriate for you. Also, if you have specific questions about clinical trials that might be appropriate for you, please reach out to our PNW Chapter Clinical Trial Education Volunteers (CTEV) Laura Tremblay (LDTremblay71@gmail.com) and/or Jude Restis (JRestis@yahoo.com).

Benaroya Research Institute

FABULINUS Study

This study is testing an investigational drug called frexalimab in people with newly-diagnosed T1D.  Frexalimab is thought to work by blocking pathways of immune cell activation and function.

You can help researchers understand:

• If frexalimab can preserve the body’s own insulin production.
• If frexalimab can help the body control blood glucose levels.
• If frexalimab can decrease the dose of insulin.
• How safe frexalimab is.

You may be eligible for this study if you are:

• Age 12-21 years old
• Newly-diagnosed with T1D in the past 3 months

If interested, please contact:  diabetes@benaroyaresearch.org, 1-800-888-4187

This study also is being conducted in Idaho Falls at the Rocky Mountain Diabetes and Osteoporosis Center:  rockymountainclinicalresearch@idahomed.com, 208-522-6005

JAKPOT STUDY

This study is looking at two different treatments – abrocitinib and ritlecitinib – to see if either or both can preserve insulin production in people newly diagnosed with T1D.  Researchers believe abrocitinib and ritlecitinib may be able to calm the immune system response that harms insulin-producing beta cells.  Both medications are already FDA-approved for other immune-mediated illnesses.  One advantage of these medications over other interventions is that they come in pill form and are taken orally, rather than being given as an injection or IV infusion.

You may be eligible for this study if you are:

• Age 12-35 years old
• Newly-diagnosed with T1D in the past 3 months

If interested, please contact:  diabetes@benaroyaresearch.org, 1-800-888-4187.

BRIDge Biorepository Study

The Diabetes Biorepository is a confidential list of people with type 1 diabetes (T1D) who donate samples and provide health information for scientific research. This library of samples and information helps BRI’s scientists study how and why T1D starts and make progress toward prevention and better treatments.

Qualifications:

• Diagnosed with T1D
• Over 1-year old
• Live in, or regularly travel to Seattle

Read more about this study here, through an interview with Megan Smithmyer, PhD, Staff Scientist at Benaroya Research Institute in the Center for Interventional Immunology.

If you are further interested in BRIDge or any of BRI’s biorepositories, you can complete an interest form online here and their team will reach out to you. If you have any other questions, you can connect with BRI by email at diabetes@benaroyaresearch.org or by phone at (800) 888-4187.

Rocky Mountain Diabetes and Osteoporosis Center – Idaho Falls

DIAGNODE-3

The purpose of this phase 3 study is to explore whether an investigational drug, Diamyd® (rhGAD65), is able to preserve the body’s own insulin-producing ability. Diamyd® prevents attack on the body’s insulin-producing beta cells by reprogramming the immune system to ignore GAD (glutamic acid decarboxylase). In T1D, GAD can give rise to autoantibodies, which tell the immune system to destroy beta cells. Over a two-month period, participants will receive three ultrasound-guided injections into a lymph node located in the groin, followed by a 22-month follow-up. For every two participants receiving Diamyd®, one will receive a placebo (a treatment with no therapeutic effect for comparison).

You may be eligible for this study if you:

• Are 12-28 years old
• Were diagnosed with T1D within the last 6 months
• Have GAD autoantibody
• Have a specific genetic marker (HLA DR3-DQ2)

You can find out more about this study here. If interested, please contact: rockymountainclinicalresearch@idahomed.com, 208-522-6005.

University of Washington

REMODEL T1D

REMODEL T1D is looking at the potential benefits of the GLP-1 agonist, Semaglutide, on kidney function in people with abnormal kidney function due to T1D.  A secondary objective is to study the glycemic effects of Semaglutide in people with T1D.  The study will last 26 weeks, including a gradual titration of study medications to maximum target dose over 12 weeks, followed by evaluation of the effect of Semaglutide on the kidney. Evaluation will include kidney MRI, urine testing and blood testing.

You may be eligible for this study if you:

• Are 18 years of age or older
• Have been diagnosed with T1D for at least 5 years
• Have abnormal kidney function due to T1D
• Are on stable doses of medications for blood pressure and cholesterol

If interested, please contact: Darinka Gil, dgm91@uw.edu

T1-DISCO – Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes

The purpose of this study is to learn more about the effects of an investigational drug called semaglutide (Ozempic™), as a safe and effective means of improving cardiovascular function, kidney function, and insulin sensitivity in adults with type 1 diabetes. Semaglutide is considered investigational because it is an FDA-approved drug being used off-label. This medication has been effective in reducing cardiovascular disease and diabetic kidney disease and improving glucose control and BMI in adults with type 2 diabetes. This study aims to look at how well the medication works in people with type 1 diabetes. Semaglutide is not approved by the FDA to be used in this way. UW will perform a randomized study to assess the effects of 8 months of once weekly subcutaneous semaglutide vs. once weekly placebo injections. If participants join the study, they will have one screening visit, one 8-month treatment phase, two long study visits, two MRI visits, four interim visits, and one follow-up visit over approximately 9 months. They will be asked to take the study medication or a placebo, for a period of 8 months.

If interested, please contact: Bri Hihara, bhihara@uw.edu

University of Washington & Seattle Children’s Hospital

MANATEE T1D

Metformin and Automated Insulin Delivery system effects on renal vascular resistance, insulin sensitivity, and cardiometabolic function in youth with type 1 diabetes.

This study is randomized, double-blind, placebo-controlled trial being conducted at Seattle Children’s Hospital and the University of Washington. The purpose of this study is to learn about the health effects on the kidney, blood vessels, and insulin sensitivity of combining two treatments – an automated insulin delivery system and metformin – for people with type 1 diabetes. The use of metformin in this study is experimental. Study participants will be randomized to receive metformin or a placebo for the study period of 4 months.

If interested, please contact: Kevin Bocek, Kevin.Bocek@seattlechildrens.org; Bentina Marin, bentina.marin@seattlechildrens.org.

Rainier Clinical Research Center

Biolinq CGM

This study involves a 7-day wear period for up to 4 Biolinq sensors, along with one Libre sensor and one Dexcom G6 sensor. Participants will conduct fingersticks at home (8 per day) and will attend one 10-hour clinic visit during the study. Compensation is up to $930. Enrolling now!

Dexcom CGM

This study involves a 15.5-day wear period for 4 Dexcom CGMs (2 on the back of the arm and 2 on the abdomen). Participants will conduct fingersticks at home (9 per day). There are no long in-clinic days for this study, only brief visits for sensor insertion and removal. Compensation is up to $715.

GLP-1/GIP Study (Eli Lilly Tirzepatide (Mounjaro Study)

This study will examine tirzepatide (Mounjaro) versus placebo, with 20% of participants randomized to placebo for the 40-week treatment period and 80% of participants randomized to tirzepatide for the 40-week treatment period. Key inclusion criteria include BMI >25 and HbA1C 7.0-10.5%. For pump users, hybrid closed-loop systems (e.g. Tandem Control IQ, Medtronic Smart Guard, Omnipod 5) are permissible. Compensation will be provided, but the amount has not yet been shared. Screening will begin in April 2025.

Hypothyroid Study – AbbVie Hypothyroidism

(This is not a type 1 diabetes study, per se. However, given hypothyroidism is an autoimmune disease, it often overlaps with type 1 diabetes.) This study will evaluate the efficacy and safety of Armour Thyroid treatment compared with synthetic T4 (Synthroid) in subjects who have primary hypothyroidism. The study will include an 81-week treatment period with an additional 9 weeks of follow-up. Key inclusion criteria include continuous use of synthetic T4 (Synthroid) for at least 12 months with no dose changes within 3 months of the screening visit, dose of synthetic T4 of 25-200mcg at the screening visit, and BMI 18-40. Compensation is up to $2000. Enrolling now!

If you are interested in one or more of the trials above, please contact the Site Coordinator at RCRC at recruitment@rainier-research.com or call 888-478-8343.

Find a Clinical Trial Near You!

If the above clinical trials and studies don’t work for you, you can utilize Breakthrough T1D and Antidote’s Clinical Trial Connection Tool to find one that resonates with you! To utilize this tool visit this link, or if you want to learn more about Clinical Trials in general, visit here.